Orbital Procedures with CC/MCC DRG Reimbursement Guide

Summary & Overview

Orbital Procedures with CC/MCC: Inpatient Reimbursement Overview

DRG 113 encompasses inpatient orbital surgical procedures when accompanied by a Complication or Comorbidity or Major Complication or Comorbidity; it includes treatments such as fracture repair, orbital decompression, and tumor excision with significant secondary diagnoses. This classification matters for inpatient reimbursement because cases with Complication or Comorbidity or Major Complication or Comorbidity typically reflect higher resource utilization and receive different Diagnosis-Related Group payment weights under Medicare.

Orbital Procedures with CC/MCCDRG Orbital Procedures with CC/MCCDRG 113Diagnosis-Related GroupInpatient ReimbursementMedicareOphthalmologyOculoplastic SurgeryOrbital Fracture RepairOrbital Decompression

DRG 113 Overview

DRG 113 covers inpatient hospital admissions for orbital procedures performed in the presence of a Complication or Comorbidity or Major Complication or Comorbidity. Clinical cases include surgical management of orbital fractures, decompression, tumor excision, or other operative orbital interventions when accompanied by significant secondary diagnoses. This group matters for Medicare payment because the presence of Complication or Comorbidity or Major Complication or Comorbidity elevates the relative resource use and therefore affects the Diagnosis-Related Group assignment and associated inpatient reimbursement. Understanding the clinical scope and coding implications helps clarify how case complexity maps to payment under Medicare rules.

National Payment Rates

Across payers the observed rate range runs from about $12K (Aetna minimum) up to $78K (Anthem maximum), with mean benchmark payments clustering roughly in the $20K–$40K range depending on payer. The widest spread is seen between Anthem and Aetna at about $66K. See the table and chart below for payer-level detail.

Mean Rates by Payer — National — DRG 113

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($27.5k), average submitted covered charges ($131.9k), average Medicare payment ($22.6k), and total discharges (417).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 113 payer means span from $37K to $57K across the reporting payers, reflecting a modestly wide rate range. Cigna stands out as the highest-paying payer, while Blue Cross Blue Shield and Anthem are tied at the low end. The Alaska pattern shows Cigna paying notably above the other state payers and above comparable national means. See the table and chart below for payer-level details.

Key Insights for Alaska

Highest payer: Cigna (mean $57K); Lowest payers: Blue Cross Blue Shield and Anthem (both mean $37K).
State range is relatively wide ($37K–$57K), with Cigna paying substantially above the other payers in Alaska.
Alaska’s highest mean ($57K) exceeds typical national means for Anthem/Aetna/Cigna in the national sample, indicating a meaningful upward deviation from national averages for Cigna in this DRG.

Clinical Trials

Acute surgical efficacy and safety trials: randomized or prospective cohort studies comparing different orbital surgical approaches (e.g., open orbital decompression techniques, transconjunctival versus external approaches) for patients presenting with acute orbital pathology such as traumatic orbital fractures, orbital cellulitis requiring drainage, or compressive optic neuropathy. These studies enroll inpatients undergoing operative management and measure short-term outcomes like visual acuity preservation, orbital compartment pressure, length of stay, perioperative complication rates, and need for reoperation. Results inform surgeons and hospital administrators about which operative strategies reduce morbidity and resource use, directly affecting inpatient costs and reimbursement profiles under this DRG.
Comparative effectiveness research on perioperative care pathways: multicenter observational studies or pragmatic trials evaluating standardized perioperative bundles (antibiotic timing/duration, steroid use, imaging protocols, and postoperative monitoring) for adults and children admitted for orbital procedures with complicating comorbidities (e.g., diabetes, immunosuppression). These studies focus on reducing infectious and thromboembolic complications, optimizing imaging utilization, and shortening ICU or ward stays by identifying which care pathways yield the best balance of clinical outcomes and resource utilization. Findings are relevant to payers and hospital case managers because they can guide protocol adoption that improves quality metrics, reduces length of stay and readmissions, and impacts cost-containment within DRG payment structures.
Longitudinal functional and quality-of-life outcomes studies after complex orbital surgery: prospective cohort studies or registry-based research following patients discharged after orbital procedures with CC/MCC to assess long-term visual function, diplopia, cosmetic outcomes, prosthetic needs, and rehabilitation services utilization. These studies often include patient-reported outcome measures, rates of secondary procedures (e.g., strabismus or orbital reconstruction), and outpatient service use over 6–24 months. Such research informs rehabilitation planning, outpatient resource allocation, and payer coverage decisions for rehabilitative and reconstructive services that affect total episode-of-care costs tied to the initial inpatient DRG.

Other Disorders of the Eye with MCC or Thrombolytic Agent: Inpatient Reimbursement Overview

114-ORBITAL-PROCEDURES-WITHOUT-CC-MCC

Orbital Procedures without CC/MCC: Inpatient Reimbursement Overview

115-EXTRAOCULAR-PROCEDURES-EXCEPT-ORBIT

Extraocular Procedures Except Orbit: Inpatient Reimbursement Overview

117-INTRAOCULAR-PROCEDURES-WITHOUT-CC-MCC

Intraocular Procedures without CC/MCC: Inpatient Reimbursement Overview

116-INTRAOCULAR-PROCEDURES-WITH-CC-MCC

Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview

121-ACUTE-MAJOR-EYE-INFECTIONS-WITH-CC-MCC

Acute Major Eye Infections with CC/MCC: Inpatient Reimbursement Overview

122-ACUTE-MAJOR-EYE-INFECTIONS-WITHOUT-CC-MCC

Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

123-NEUROLOGICAL-EYE-DISORDERS

Neurological Eye Disorders: Inpatient Reimbursement Overview

125-OTHER-DISORDERS-OF-THE-EYE-WITHOUT-MCC

Other Disorders of the Eye without MCC: Inpatient Reimbursement Overview

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$28K	$130K	$23K	420